The present invention relates to novel Factor VII or VIIa variants comprisinga substitution in at least one position selected from the group consisting ofL39, 142, S43, K62, L65, F71, E82 and F275, which are positions involved intissue factor binding. Such variants exhibit increased clotting activity ascompared to human wild-type Factor VIIa. The present invention also relates touse of such Factor VII or VIIa variants in therapy, in particular for thetreatment of a variety of coagulation-related disorders.
